Medtronic snagged a CE mark for the Export Advance aspiration catheter, planning to launch the clot-removing device in Europe and other international markets.
Sanofi can't shake the underproductive R&D site in Toulouse, France, without a fight from workers and French government officials. In the latest chapter of the ongoing feud, the Paris-based drug giant and a familiar critic in France's government show how far apart they stand on the fate of the research operation that brought the world the blood-thinner
St Jude Medical has won European clearance for the Ilumien Optis PCI Optimization System, technology designed to help treat coronary artery disease by modeling vessels and guiding stent placement.
An active pharmaceutical ingredient facility in Cork County, Ireland, has been targeted for closure next year, although Pfizer hopes its can save the 136 jobs there by selling it to another drugmaker.
The long and colorful Poly Implant Prothèse saga is slowly drawing to a close, as prosecutors are asking for a four-year jail sentence and $128,000 fine for the CEO who presided over the sale of faulty breast implants to thousands of women.
While Abbott Laboratories leads the way in the dissolvable stent market, California's Elixir Medical is right on its heels, winning CE mark approval for the DESolve device.
Tokyo-based Astellas Pharma is rolling out a major R&D restructuring effort, shuttering facilities at its OSI Pharmaceuticals and Perseid Therapeutics subsidiaries and cutting back its work at the Astellas Research Institute of America to focus solely on CNS diseases.
Abbott Laboratories has locked down European approval for a new diabetes diagnostic, getting the green light to market a test that can help diagnose and monitor diabetics as well as flag patients at risk for developing the disease.
The lag time between the groundbreaking of a drug-manufacturing plant and when it is completed is usually measured in years. But Penn Pharma says in the case of its new facility in Wales, it was able to cut that time to months.
A Novartis over-the-counter manufacturing plant in Switzerland is receiving a new lease on life after giving CEO Joseph Jimenez what he wants, while the OTC plant in Lincoln, NE, is feeling the sting of failing to do so.